期刊
JOURNAL OF CONTROLLED RELEASE
卷 170, 期 3, 页码 460-468出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2013.06.012
关键词
PPAR gamma agonists; Macrophage targeting; PLGA/PVA nanospheres; Inflammatory diseases
资金
- EU Commission
- European Social Fund
- Department 11 Culture-Education-University-Research-Technological Innovation - Higher Education of Calabria Region (POR Calabria FSE)
PPAR gamma nuclear receptor agonists have been shown to attenuate macrophage inflammatory responses implicated in the metabolic complications of obesity and in atherosclerosis. However, PPAR gamma agonists currently in clinical use, including rosiglitazone (RSG), are often associated with severe side effects that limit their therapeutic use. Here, 200 nm PLGA/PVA nanospheres were formulated for the systemic delivery of RSG specifically to macrophages. RSG was encapsulated with over 50% efficiency in the hydrophobic PLGA core and released specifically within the acidifying macrophage phagosomes. In bone marrow derived macrophages, RSG-loaded nanoparticles (RSG-NPs) induce a dose dependent upregulation (1.5 to 2.5-fold) of known PPAR gamma target genes, with maximal induction at 5 mu M; and downregulate the expression of genes related to the inflammatory process, with a maximum effect at 10 mu M. In Ldlr(-/-) mice fed high fat diet, treatment with RSG-NPs alleviated inflammation in white adipose tissue and liver but, unlike treatment with free RSG, did not alter genes associated with lipid metabolism or cardiac function, indicating a reduction in the RSG side effect profile. These biocompatible, biodegradable RSG-NPs represent a preliminary step towards the specific delivery of nuclear receptor agonists for the treatment of macrophage-mediated inflammatory conditions associated with obesity, atherosclerosis and other chronic disease states. (C) 2013 Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据